total debt total asset
report better-than-expect fiscal result strong revenu
million versu consensu expect million drive
out-performance adjust ep versu consensu expect
quarter compani achiev constant currenc organ
growth exceed forecast driven strength
healthcar specialti servic organ appli steril
technolog organ custom inventori build ahead
prior brexit deadlin ste transit manufactur barrier
product anoth facil ad million combin compani
revenu healthcar product life scienc ste organ growth
still would exclud time issu notabl ste
healthcar equip organ growth roughli posit surpris
compani healthcar equip order backlog also year-
over-year million end fiscal suggest favor
trend continu
expect constant currenc organ growth adjust
ep versu prior consensu expect free
cash flow million million note
compani organ growth guidanc includ impact expect
million lost sale relat previous announc restructur effort
specif discontinu certain sercon steril eschmann surgic
tabl transit manufactur remain product line
brand locat regard free cash flow expect
cash flow oper increas roughli year-over-year
million howev compani anticip substanti increas
capit expenditur next year well year-over-year
million includ million support build addit termin steril
capac appli steril divis note
build addit termin steril capac appli steril
technolog busi unless contract place justifi increment
capac view move posit sign regard demand trend
appli steril technolog medium term like reflect
favor market demand market share gain sterigen
rais adjust ep estim
new adjust ep forecast compani
deliv strong result across four divis fiscal
compani appear well posit maintain improv growth trajectori
infect prevent equip strong custom demand appli
steril technolog encourag custom respons
outsourc reprocess center initi reiter buy rate
increas price target
import pleas read disclosur disclaim page report
report fiscal adjust ep consensu expect higher
estim better-than-anticip revenu contribut upsid rel adjust ep
forecast quarter
ste fiscal revenu increas year-over-year million well consensu
expect million estim quarter compani achiev constant
currenc organ growth exceed forecast custom inventori build ahead
plcfiscal adjust incom statement revenu analysisnorthcoast research thousand except percentag per share gross sg sg oper oper interest expens incom incom tax incom margin incom com share growth ep growth life appli steril healthcar specialti compani report northcoast research estim factset reflect adopt prior brexit deadlin ste transit manufactur barrier product anoth facil ad
million compani revenu organ growth still would exclud item
growth posit fiscal forecast
quarter organ growth strong across healthcar product divis includ improv roughli
year-over-year healthcar servic year-over-year healthcar consum year-over-year
healthcar capit includ similar perform infect prevent oper room equip
time custom inventori build ahead prior brexit deadlin contribut million
steri plcorgan growth analysi benefit signific year-over-year increas shipment hurt difficult year-over-year comparison shipmentssourc compani report northcoast research plchealthcar product organ growth analysi benefit signific year-over-year increas shipment hurt difficult year-over-year comparison shipmentssourc compani report northcoast research increment revenu quarter result still would easili exceed forecast without benefit
notabl ste healthcar equip order backlog also year-over-year million end
fiscal suggest favor trend continu think combin posit healthcar capit
market trend strength ste strong new product offer includ new amsco steam steril
amsco washer v-pro low temperatur steril system hexavu integr system
clean suit ceil system aid healthcar backlog posit
fiscal ste life scienc busi post organ growth estim
consist expect difficult comp softer backlog hurt fiscal life scienc capit equip
sale lead roughli organ growth declin life scienc capit sale quarter contrast life
scienc consum sale particularli strong approxim organ quarter aid part
custom inventori build barrier product move manufactur item anoth
facil custom expect work barrier product inventori fiscal
encourag see ste life scienc equip backlog return rel flat growth exit fiscal
follow mid-single-digit low-double-digit year-over-year declin past three quarter
ste appli steril ast busi achiev organ growth fiscal
well forecast note result even stronger initi appear ste ast busi
face roughli million revenu headwind exit sterilm contract august exclud
steri plcorder backlog analysi northcoast researchord backlog order scienc order scienc compani report northcoast research estim aid black diamond video acquisitionsteri plclife scienc divis organ growth analysi compani report northcoast research item ste core ast revenu closer quarter compani point increas demand
core medic devic custom primari growth driver ast quarter think capac
expans favor price least modest volum benefit mid-februari closur
sterigen ethylen oxid termin steril facil willowbrook illinoi help well addit
complet decemb acquisit herotron e-beam servic gmbh compani annual revenu
single-digit million rang may contribut modestli quarter perform
ste healthcar specialti servic busi achiev constant currenc organ growth fiscal
forecast aid encourag perform instrument repair
outsourc steril process busi notabl estim ste outsourc reprocess center revenu
million rang initi million target increment revenu
busi expect similar rang would guess million roughli million moreov
 outsourc reprocess center busi continu ramp think good visibl ste
healthcar specialti servic divis double-digit grower
ste fiscal adjust oper margin increas bp year-over-year slightli
estim quarter adjust gross margin particularli strong bp year-over-year
higher performance-bas compens contribut increas adjust oper expens
percent sale
expect constant currenc organ growth adjust ep versu prior
consensu expect free cash flow million million note
compani organ growth guidanc includ impact expect million lost sale relat
previous announc restructur effort specif discontinu certain sercon steril eschmann
surgic tabl transit manufactur remain product line brand locat
regard free cash flow expect cash flow oper increas roughli year-
over-year million howev compani anticip substanti increas capit expenditur next
year well year-over-year million includ million support build addit
termin steril capac appli steril divis note build
addit termin steril capac appli steril busi unless contract
place justifi increment capac view move posit sign regard demand trend
appli steril technolog medium term like reflect favor market demand
market share gain sterigen
rais adjust ep estim new adjust ep forecast
compani
summari deliv strong result across four divis fiscal compani appear well
posit maintain improv growth trajectori behind healthi healthcar capit backlog favor
product launch activ infect prevent equip strong custom demand appli steril
technolog encourag custom respons outsourc reprocess center initi
moreov think restructur effort announc decemb give investor greater comfort
ste abil achiev bp adjust oper margin expans reiter
buy rate increas price target
plcadjust oper margin healthcar life appli steril healthcar specialti fiscal exclud corpor expensesourc compani report northcoast research
steri plcannual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg oper oper net interest expens interest net expens incom incom incom tax minor net incom extra net margin extra extra net incom continu net wghd com share ep ep revenu growth adjust ep growth compani report northcoast research estim result adjust reflect adopt disclosur
